1 completed, 1 withdrawn. 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Unresectable Bone Sarcoma: new trials by email Literature Review of Unresectable Bone Sarcoma trials Research Report on Unresectable Bone Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine With Ascorbate Including Adolescents Ascorbate, Gemcitabine - Soft Tissue Sarcoma, Bone Sarcoma | Early Phase 1 | Withdrawn | David Dickens | 2023-01-01 | 2023-02-22 | |
| Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 164 | 2015-08-13 | 2023-10-17 |
Bone Neoplasms (2) · Sarcoma (2) · Histiocytoma, Malignant Fibrous (1) · Liposarcoma (1)
Bone Diseases (2) · Musculoskeletal Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Connective and Soft Tissue (2) · Histiocytoma (1) · Neoplasms, Adipose Tissue (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Fibrous Tissue (1)
Ascorbic Acid (1) · CTLA-4 Antigen (1) · Gemcitabine (1) · Ipilimumab (1) · Nivolumab (1)
David Dickens (1) · National Cancer Institute (NCI) (1)
United States (2)
David Dickens, MD, FAAP (1) · Sandra P D'Angelo (1)
U10CA180821 (1)